The present invention relates to a fusion protein for enhancing gene editing and use thereof. In particular, the invention provides an enhanced fusion protein. The enhanced fusion proteins of the present invention can significantly increase gene editing efficiency in vivo or in vitro as compared to the wildtype gene editing protein.

The present invention relates to a fusion polypeptide that inhibits TLR1/2, TLR2/6, TLR7, TLR8 and TLR9 signaling pathways as well as Toll-like receptor 4 (TLR4) and TLR3, and a pharmaceutical composition for preventing or treating TLR pathway mediated diseases. The fusion peptide of the present invention has an excellent effect of inhibiting TLR4 and various TLR pathways and can be effectively used in preventing and treating various TLR pathway mediated diseases caused by the signaling pathways, such as autoimmune diseases, inflammatory diseases and degenerative neurological diseases, by inhibiting the TLR mediated immune responses.

Provided herein are agents, compositions, and methods useful for animal health, e.g., for altering the level, activity, or metabolism of one or more microorganisms resident in a host insect (e.g., arthropod, e.g., insect, e.g., pathogen vector), the alteration resulting in a decrease in the fitness of the host. The invention features a composition that includes an agent (e.g., phage, peptide, small molecule, antibiotic, or combinations thereof) that can alter the host's microbiota in a manner that is detrimental to the host. By disrupting microbial levels, microbial activity, microbial metabolism, or microbial diversity, the agents described herein may be used to decrease the fitness of a variety of insects that carry vector-borne pathogens that cause disease in animals.

Provided herein is a novel screening method for a client protein-protecting protein, and a physiologically active protein-stabilizing protein and a pharmaceutical composition using the protein. Also provided herein is a method for screening for a client protein-protecting protein, including the step of evaluating stability of a client protein in the presence of a protein having an intrinsically disordered structure. Also provided herein is an agent for stabilizing a physiologically active protein comprising, as an active ingredient, a protein having any one of amino acid sequences of SEQ ID NOs: 1 to 6; and a pharmaceutical composition including the protein and a physiologically active protein.

The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases.

This invention relates to elastomeric protein and elastomeric protein production. In particular, the invention is directed to elastomeric protein sequences, including methods and compositions for production of elastomeric protein sequences, such as expression constructs, and host cells, and including compositions generated from the elastomeric protein sequences.

The present invention belongs to the field of pharmaceutical formulations, and relates to a composition comprising a derivative of a wild-type cell-penetrating peptide penetratin and a drug having positive charge under physiological pH conditions. The derivative of the wild-type cell-penetrating peptide penetratin is a lipophilic derivative designed by using the wild-type cell-penetrating peptide penetratin, and the molecule is positively charged as a whole under physiological pH conditions. Said composition of the present invention, as an ocular drug delivery system, can enable a drug positively charged under physiological pH conditions to be absorbed to the posterior segment of the eye by means of eye dropping, thereby providing a new route for achieving ocular delivery of a drug positively charged under physiological pH conditions.

Systems, compositions, and methods for target site-specific insertion of a transgene of interest to a subject genome are provided. Systems and methods that facilitate primed reverse transcription (TPRT) mediated by retroelement derived reverse transcriptase (RTs) site-specific transgene insertion are also provided.

The invention provides an isolated peptide comprising a lysine 3-hydroxybutyrylation site, a lysine 3-hydroxybutyrylation specific affinity reagent that specifically binds to the peptide, and a method for detecting protein lysine 3-hydroxybutyrylation in a sample using the reagent.

Provided herein are methods and compositions for purifying antibodies. Purification is achieved by increasing the binding capacity of protein A chromatography by covalent attachment of a protein A domain (E, D, A, B, C), or domain Z, or a functional variant thereof, to Drosophila melanogaster transcription factor Ultrabithorax (Ubx) materials. The compositions include fusion proteins containing Drosophila melanogaster transcription factor Ultrabithorax (Ubx) or a fragment thereof and an immunoglobulin binding protein. In some embodiments, the immunoglobulin binding protein is a protein A domain, a protein Z domain or a fragment thereof.